VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market
Viridian eye disease drug benefits chronic patients in late-stage trial
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Short Interest Update
Traders Buy Large Volume of Put Options on Viridian Therapeutics (NASDAQ:VRDN)
Why Is Viridian Therapeutics Stock Sinking Monday?
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics shares fall over 30% after trial data disappoints
Why Is Viridian Therapeutics Stock Falling Monday?
Viridian Therapeutics shares fall over 30% after trial data disappoints
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $42.64 Average Target Price from Brokerages
Campbell & CO Investment Adviser LLC Takes Position in Viridian Therapeutics, Inc. $VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Prepares for Transformational 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of “Moderate Buy” from Brokerages
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fisher Asset Management LLC Lowers Stake in Viridian Therapeutics, Inc. $VRDN
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Is Ready For An Eventful 2026
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress